T1	Pharmacological_substance 30 42	itraconazole
N1000 	Reference T1 MeSH:D017964	itraconazole
T2	Pharmacological_substance 126 137	haloperidol
N1001 	Reference T2 MeSH:D006220	haloperidol
T5	Pharmacological_substance 234 246	itraconazole
N1002 	Reference T5 MeSH:D017964	itraconazole
T7	Pharmacological_substance 322 333	haloperidol
N1003 	Reference T7 MeSH:D006220	haloperidol
T21	Pharmacological_substance 664 675	haloperidol
N1004 	Reference T21 MeSH:D006220	haloperidol
T23	Pharmacological_substance 809 820	haloperidol
N1005 	Reference T23 MeSH:D006220	haloperidol
T24	Pharmacological_substance 860 872	itraconazole
N1006 	Reference T24 MeSH:D017964	itraconazole
T26	Pharmacological_substance 937 949	Itraconazole
N1007 	Reference T26 MeSH:D017964	Itraconazole
T27	Pharmacological_substance 1033 1044	haloperidol
N1008 	Reference T27 MeSH:D006220	haloperidol
T37	Pharmacological_substance 1314 1326	itraconazole
N1009 	Reference T37 MeSH:D017964	itraconazole
T41	Pharmacological_substance 1384 1395	haloperidol
N1010 	Reference T41 MeSH:D006220	haloperidol
T47	Pharmacological_substance 1556 1568	itraconazole
N1011 	Reference T47 MeSH:D017964	itraconazole
T48	Pharmacological_substance 1614 1625	haloperidol
N1012 	Reference T48 MeSH:D006220	haloperidol
T53	Pharmacological_substance 1752 1764	itraconazole
N1013 	Reference T53 MeSH:D017964	itraconazole
T58	Pharmacological_substance 2037 2049	itraconazole
N1014 	Reference T58 MeSH:D017964	itraconazole
T61	Pharmacological_substance 2310 2322	itraconazole
N1015 	Reference T61 MeSH:D017964	itraconazole
T63	Pharmacological_substance 2488 2499	haloperidol
N1016 	Reference T63 MeSH:D006220	haloperidol
T64	Pharmacological_substance 2541 2553	itraconazole
N1017 	Reference T64 MeSH:D017964	itraconazole
T8	Subject 141 157	healthy subjects
T10	Subject 377 393	healthy subjects
T12	Subject 396 423	Nineteen healthy volunteers
T13	Pharmacological_substance 849 856	placebo
N1018 	Reference T13 MeSH:D010919	placebo
T71	Subject 255 273	CYP2D6*10 genotype
T73	Subject 47 77	CYP2D6*10 genetic polymorphism
T76	Subject 430 446	CYP2D6 genotypes
T77	Subject 481 498	9 for CYP2D6*1/*1
T78	Subject 503 523	10 for CYP2D6*10/*10
T79	Subject 527 540	Four subjects
T80	Subject 542 559	1 for CYP2D6*1/*1
T81	Subject 564 583	3 for CYP2D6*10/*10
T83	Disorder 742 765	neurologic side effects
T84	Disorder 721 737	QTc prolongation
N1 	Reference T84 UMLS:C0151878	QTc prolongation
T87	Pharmacological_substance 1064 1071	placebo
N1019 	Reference T87 MeSH:D010919	placebo
T91	Subject 1133 1169	subjects with CYP2D6*10/*10 genotype
T92	Subject 1212 1246	subjects with CYP2D6*1/*1 genotype
T93	Subject 1328 1355	subjects with CYP2D6*10/*10
T94	Subject 1435 1469	subjects with CYP2D6*1/*1 genotype
T39	Combination 833 845	pretreatment
T44	Pharmacological_substance 1416 1423	placebo
N1020 	Reference T44 MeSH:D010919	placebo
T57	Pharmacological_substance 1880 1887	placebo
N1021 	Reference T57 MeSH:D010919	placebo
